替普瑞酮临床治疗慢性萎缩性胃炎的疗效

目的：观察替普瑞酮治疗萎缩性胃炎的临床疗效。方法：205例慢性萎缩性胃炎（chronic atrophic gastritis，CAG）患者随机分为两组，治疗组（101例）连续口服替普瑞酮胶囊，对照组（104例）口服安慰剂，总疗程20周。观察两组治疗前后症状、胃镜检查及胃黏膜组织学检查改变。结果：治疗组临床症状改善有效率87．1％，对照组52．9％，两组比较差异有统计学意义（P〈0．05）；胃镜下黏膜改变：治疗组总有效率92．1％，对照组60．6％，两组比较差异有统计学意义（P〈0．05）。胃黏膜组织学变化比较显示：治疗组总有效率为90．1％，对照组54．8％，两组比较差异有统计学意义（P〈0．05）。结论：替普瑞酮是治疗慢性萎缩性胃炎安全有效的药物。

Efficacy of teprenone in treatment of atrophic gastritis

Objective：To investigate the efficacy of teprenone in the treatment of atrophic gastritis. Methods： 205 patients with atrophic gastritis were randomly divided into 2 groups, to receive a 20-week therapy with teprenone （teprenone treatment group, n = 101 ） or with placebo （ control group, n = 104 ）. Major symptoms, findings of gastroscopy and histology of gastric mucosa were recorded before and after the treatment,and compared between the two groups. Results： The rates of response in the teprenone treatment group was 87.1% vs 52.9% in the control group by symptom relief （ P 〈 0.05 ）, 92.1% vs 60.6% by gastroscopy （ P 〈 0.05 ）, and 90. 1% vs 54.8% by histology（P 〈0.05）. Conclusion： Teprenone can safely and effectively protect against chronic atrophic gastritis.